These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16625144)

  • 41. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
    Cancado R; Olivato MC; Bruniera P; Szarf G; de Moraes Bastos R; Rezende Melo M; Chiattone C
    Acta Haematol; 2012; 128(2):113-8. PubMed ID: 22760067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
    Ruffo GB; Borsellino Z; Cuccia L; Marocco MR; Gagliardotto F; Tarantino R
    Clin Drug Investig; 2010; 30(4):267-73. PubMed ID: 20225910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delineating parameters of iron overload in MDS patients treated with deferasirox.
    Leitch HA
    Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
    [No Abstract]   [Full Text] [Related]  

  • 45. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 47. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
    Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron-chelating therapy for transfusional iron overload.
    Brittenham GM
    N Engl J Med; 2011 Jan; 364(2):146-56. PubMed ID: 21226580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
    Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
    Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.
    Kim J; Kim Y
    Value Health; 2009; 12 Suppl 3():S78-81. PubMed ID: 20586988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
    Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
    Rheault MN; Bechtel H; Neglia JP; Kashtan CE
    Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exjade (ICL 670): A new oral iron chelator.
    Agarwal MB
    J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB
    Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R; Campus S; Origa R
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 58. Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox.
    Pazgal I; Brown M; Perets TT; Niv Y; Rachmilewitz E; Stark P
    Am J Hematol; 2014 Sep; 89(9):938-9. PubMed ID: 24923845
    [No Abstract]   [Full Text] [Related]  

  • 59. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
    Ghoti H; Fibach E; Merkel D; Perez-Avraham G; Grisariu S; Rachmilewitz EA
    Haematologica; 2010 Aug; 95(8):1433-4. PubMed ID: 20421274
    [No Abstract]   [Full Text] [Related]  

  • 60. [Post transfusionnal iron overload].
    Rose C
    Rev Prat; 2006 Dec; 56(19):2141-5. PubMed ID: 17416052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.